Adis Clinical Trials Insight [173,373,873,973]

HOME : Support : Dialog Search Aids : Bluesheets
View Bluesheets by \| Database Name \| File Number \| Subject \| OneSearch Categories \| Search Options \|

	173,373,873,973
Adis Clinical Trials Insight

Last Loaded on Web: Wednesday, May 01, 2013

Last Update To Bluesheet: December 17, 2009

Bluesheet Contents PDF version

File Description	Dialog File Data	DIALINDEX/OneSearch Categories	Basic Index	Rank
Subject Coverage	Document Types Indexed	Contact	Additional Indexes	Map
Tips	Geographic Coverage	Terms and Conditions	Limit	Predefined Format Options
Print Counterparts	Special Features	Sample Record	Sort	Rates

File Description [top]

Adis Clinical Trials Insight presents highly structured records of key papers, published in more than 1,300 international medical and biomedical journals, papers presented at 100 meetings and clinical data from media releases and relevant company and trial registry Web sites on drugs, drug therapy, adverse drug reactions, and pharmacoeconomics. Document types include Best Evidence, Supporting Evidence, and Ongoing Trial records.

Summaries are presented in a highly structured and consistent format to provide a clear definition of the study and results. Drug regimens, results and side effects, etc., are presented in easy-to- read tables. Adis Clinical Trials Insight also provides an evaluation score for clinical trials (applicable to Best Evidence records only) as an independent guide to the quality of the trial, design, and reporting.

Files 173 & 973 include all record types. Files 373 & 873 include the former Summary and Citation records. Files 873 and 973 are subscriber files.

Tips [top]

USE FILE 173

to search for information on drugs, drug therapy, adverse drug reactions, and pharmacoeconomics.

USE AC= and CC=

to create a set of records by WHO or EphMRA category

SELECT AC=L01A

SELECT UD=YYYYMMDD

to create a set of New, Significantly Modified, and Modified records in a given update

USE DT=ONGOING TRIAL

to isolate records that profile a trial

USE ST=

to see the various Study Status options of Ongoing Trial records

EXPAND ST=

USE SK=

to search Endpoints and biomarkers

SELECT SK=BIOMARK?

MAP LK in File 107

to find related records

SELECT LK=019461;MAP LK;B107;EXS

Subject Coverage [top]

Affective Disorders
Alzheimer's & Cognition Disorders
Antibacterials
Antithrombotics
Antivirals
Anxiety Disorders
Arrhythmias
Cancer Chemotherapy
Diabetes
Epilepsy and Seizure Disorders
Heart Failure
Hyperlipidaemia
Hypertension
Irritable Bowel Syndrome
Ischaemic Heart Disease
Men's Health
Nausea & Migraine
Neurological Disorders
Obesity
Obstructive Airways Disease
Pain Control
Parkinson's Disease
Peptic Ulcer Disease
Pharmacoeconomics
Psychotic Disorders
Rheumatic Disease
Transplant Rejection
Vaccines
Women's Health

Print Counterparts [top]

Adis Clinical Trials Insight Classics

Dialog File Data [top]

Dates Covered:	1990-present (File 173) 1982-1989 (File 373) 1982-1989 (File 873) 1990-present (File 973)
File Size:	More than 536,000 records as of December 2009 (File 173) 38,791 records (File 373)
Update Frequency:	Weekly (File 173) Closed (File 373) Closed (File 873) Weekly (File 973)

Document Types Indexed [top]

Bibliographies
Journal Articles
Complete Text

Geographic Coverage [top]

International

Geographic Restrictions [top]

None

Special Features [top]

ERA Available (REDIST only)
KWIC and HILIGHT Available
DIALOG Alert Available
Remove Duplicates (RD, ID) Available

DialIndex/OneSearch Categories [top]

ACRONYM	CATEGORY NAME
ADIS	Adis Files
DRUGDEV	Drug Development Pipeline
DRUGECON	Pharmacoeconomics
PHARM	Pharmacology

Contact [top]

ADIS Clinical Trials Insight is produced by Wolters Kluwer Pharma Solutions. Questions concerning file content should be directed to:

Wolters Kluwer Pharma Solutions
Sarah Schweer
Client Services Department
770 Township Line Road, Suite 300
Yardley, PA 19067

Telephone:	+1-267-757-3421 ex 1
800 Line:	1-877-872-2347 ex 1
Fax:	1-267-757-0652
E-Mail:	Sarah.Schweer@wolterskluwer.com

Wolters Kluwer Pharma Solutions
Client Services Department
250 Waterloo Road
London, SE1 8RD
United Kingdom

Telephone:	+44 20 7981 0764
Fax:	+44 20 7981 0564
E-Mail:	sarah.schweer@wolterskluwer.com

Terms and Conditions [top]

For Dialog's Redistribution and Archive Policy, enter HELP ERA online. The following terms and conditions also apply.

Database copyrighted by Adis Data Information BV. Data may not be duplicated in hard copy or machine-readable format without written permission of Adis Data Information BV.

If data is to be distributed under Dialog's Redistribution and Archiving (ERA) policy, distribution is restricted to the company and geographical boundaries of the country where the data was downloaded. Data which has been downloaded under this provision may not be sold or resold to a third party outside the company organization.

Dialog Standard Terms & Conditions apply.

SAMPLE RECORD [top]

	`DIALOG(R)File 173:Adis Clinical Trials Insight`
	`(c) 2009 Wolters Kluwer Pharma Sol. All rts reserv`

AA=	`0000104589 801040717`
/TI	`ADIS TITLE:`
	`Methotrexate: therapeutic use; Rheumatoid arthritis; In patients with`
	`undifferentiated arthritis: PROMPT study`
/TI	`ORIGINAL TITLE:`
	`Probable rheumatoid arthritis methotrexate versus placebo therapy`
	`(PROMPT)-study: indications for a window of opportunity in the treatment`
	`of patients with undifferentiated arthritis.`
CD=	`ADIS CREATION DATE: 7 July 2006 (20060707)`
PD=,PY=	`PUBLICATION DATE: 1 July 2006 ( 20060701 )`
AU=	`AUTHOR(S):`
	`Van Dongen H; Van Aken J; Lard LR; Ronday HK; Speyer I; Westedt ML;`
	`Allaart CF; Toes REM; Breedveld FC; Huizinga TWJ`
CS=	`CORPORATE SOURCE:`
	`Leiden University Medical Center, Leiden, The Netherlands`
JN=,SN=,SO=	`JOURNAL NAME:`
	`Annals of the Rheumatic Diseases (Ann-Rheum-Dis) 0003-4967 65 (Suppl.`
	`II): 54 (plus oral presentation) abstr. OP0001, Jul 2006`
AS=	`THERAPEUTIC AREA:`
	`Rheumatic Disease`
DT=	`DOCUMENT TYPE: Best Evidence`
LA=	`LANGUAGE: English`
MT=	`MEETING NAME:`
	`Annual European Congress of Rheumatology (2006 : June 2006 : Amsterdam,`
	`Netherlands)`
NS=	`STUDY NAME:`
	`- Probable RA: Methotrexate vs Placebo Therapy (PROMPT)`
CI=	`CLINICAL RELEVANCE:`
	`A`
/EV,OT=	`OUTCOME:`
	`Efficacy: Methotrexate > Placebo`
/EV,SM=	`STUDY MESSAGES:`
	`Efficacy: Methotrexate is beneficial in patients with undifferentiated`
	`arthritis fulfilling the criteria for probable rheumatoid arthritis.`
/EV,RH=	`RESULTS HIGHLIGHTS:`
	`Efficacy: Methotrexate was beneficial in patients with undifferentiated`
	`arthritis fulfilling the criteria for probable rheumatoid arthritis.`
	`Rheumatoid arthritis was diagnosed in 20% of methotrexate recipients`
	`compared with 29% in the placebo group. In patients with erosive`
	`disease, the rate of radiographic progression was significantly lower`
	`in methotrexate than placebo recipients (p<0.05).`
/EV,AE=	`ADIS ASSESSMENT:`
	`Adis Comment: Methotrexate, an antimetabolite agent, is well established`
	`in the treatment of malignancies and autoimmune diseases such as`
	`rheumatoid arthritis. It acts specifically by inhibiting folic acid`
	`metabolism. In rheumatoid arthritis, the action of methotrexate`
	`appears to involve interference in immune function which may play a`
	`role in the pathogenesis of the disease.Professor Tom Huizinga, one`
	`of the study investigators, comments that the PROMPT data are`
	`"excellent news" as they show "that methotrexate appears to delay or`
	`even prevent progression to rheumatoid arthritis." Another PROMPT`
	`investigator, Henrike Van Dongen, says that "one of the most`
	`interesting findings from the study was that the patients who`
	`benefited the most were the ones showing a positive anti-CCP test,`
	`which would in general terms show that a patient has a very high`
	`likelihood of developing full-blown rheumatoid arthritis; however,`
	`this study indicates that the progression to a full-blown disease`
	`amongst these patients could be influenced." This study was published`
	`as an abstract in the proceedings of the 2006 Annual European`
	`Congress of Rheumatology (EULAR) held in Amsterdam, The Netherlands,`
	`in June 2006. Additional information used in this assessment was`
	`presented orally at the conference.`
/TX	`STUDY PURPOSE:`
	`This study investigated the benefits of methotrexate treatment in`
	`patients with undifferentiated arthritis fulfilling the 1958 American`
	`College of Rheumatology (ACR) criteria for probable rheumatoid`
	`arthritis. The primary endpoints were the rates of rheumatoid arthritis`
	`(according to the 1987 ACR criteria) and radiographic progression`
	`(according to the Sharp/van der Heijde scores).`
/TX	`AUTHOR COMMENT:`
	`"Patients with UA (undifferentiated arthritis) fulfilling the ACR 1958`
	`criteria for probable RA (rheumatoid arthritis) benefit from treatment`
	`with MTX (methotrexate). Fewer patients fulfil the ACR 1987 criteria for`
	`RA and they do so at a later time point. MTX treatment also resulted in`
	`less progression in radiographic joint damage. Anti-CCP (citrullinated`
	`peptide)-positive patients seem to benefit most from treatment with MTX,`
	`which indicates the existence of a window of opportunity in`
	`anti-CCP-positive arthritic patients to influence the disease`
	`progression into full-blown RA. This is the first RCT (randomised`
	`controlled trial) that demonstrates the existence of such a window of`
	`opportunity."`
/TX	`STUDY DETAILS:`
SI=	`Design: double-blind, multicentre, randomised`
	`Control: placebo comparison, baseline comparison`
PS=	`Phase: III`
SK=	`Endpoints: Kaplan-Meier-survival-rate, Disease-progression-rate,`
	`Radiographic-outcomes, Remission-rate,`
	`American-College-of-Rheumatology-criteria, Time-to-disease-occurrence`
	`Name: Probable RA: Methotrexate vs Placebo Therapy (PROMPT)`
	`SUBJECT DETAILS:`
	`Type: patients`
	`No: 110`
	`Age: mean 51 years`
	`Sex: not stated`
	`Location: Unknown`
	`Disease: Rheumatoid-arthritis`
	`Patient Inclusion: undifferentiated arthritis fulfilling the 1958 ACR`
	`criteria for probable rheumatoid arthritis, duration of symptoms <=2`
	`years`

PK=	`Patient Age Keywords: adult`
/TX	`TREATMENTS:`
	`Methotrexate`
	`--------------------------------------------------------------------`
	`Drug/Treatment Dose Route Frequency Duration`
	`--------------------------------------------------------------------`
	`Methotrexate 15-30 mg/week PO 1/week >12 months`
	`--------------------------------------------------------------------`
	`Placebo`
	`Placebo`

	`RESULTS:`
	`--------------------------------------------------------------------`
	`Outcomes (% patients) Placebo Methotrexate`
	`--------------------------------------------------------------------`
	`Rheumatoid arthritis 29 20`
	`Remission 11 18`
	`--------------------------------------------------------------------`

	`ATC CODES:`
AC=	`WHO: L01BA01`
CC=	`EPhMRA: L01B`
/DE, /DU, /DI	`DESCRIPTORS:`
	`DRUG: Methotrexate, therapeutic use`
	`DISEASE: Rheumatoid arthritis, treatment`

LK=	`R&D INSIGHT LINK(S):`
	`020557; 021340`

BASIC INDEX [top]

SEARCH SUFFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
None	None	All Basic Index Fields	Word	S STAGE(W)I(W)HYPERTENSION
/CR	CR	References^1,3	Word	S ELI(W)LILLY/CR
/DE	DE	Descriptor	Word & Phrase	S CANDESARTAN(W)CILEXETIL/DE S HYPERTENSION(L)PREVENTION/DE
/DI	DI	Disease Descriptors	Phrase	S RHEUMATOID ARTHRITIS/DI
/DU	DU	Drug Descriptors	Phrase & Word & Phrase	S METHOTREXATE(L)THERAPEUTIC?/DU S METHOTREXATE/DU S METHOTREXATE(L)THERAPEUTIC USE/DI
/EV	EV	Evaluation	Word	S PLACEBO(W)RECIPIENTS/EV
/NA	DG	Drug Name^1,2	Phrase	S CANDESARTAN-CILEXETIL/NA
/OD	OD	Other Descriptors¹	Word & Phrase	S RESEARCH(1W)DEVELOPMENT/OD S RESEARCH "AND" DEVELOP?/OD
/PR	PR	Pharmacoeconomic Desciptors	Word & Phrase	S DECISION(W)ANALYSIS/PR S MANAGED CARE/PR
/SE	SE	Side Effects⁴	Word	S NEUROLOGICAL/SE
/TI	TI	Adis Title and Original Title	Word	S METHOTREXATE(S)RHEUMATOID/TI
/TX	AF	Adverse Effects¹	Word	S CLINICAL(W)CURE/TX
/TX	CA	Case Details⁴	Word	S TREATING(W)GABHS/TX
/TX	CT	Author Comment¹	Word	S PATIENTS(1W)UA/TX
/TX	OC	Ongoing Trials Comment^1,3	Word	S ARTHRITIS(2N)METHOTREXATE/TX
/TX	PU	Study Purpose¹	Word	S BENEFITS(1W)METHOTREXATE/TX
/TX	RE	Results¹	Word	S ARTHRITIS(1W)REMISSION/TX
/TX	SD	Study Details¹	Word	S DOUBLE(W)BLIND/TX
/TX	SJ	Subject Details¹	Word	S UNDIFFERENTIATED(W)ARTHRI?/TX
/TX	TR	Treatments¹	Word	S METHOTREXATE/TX
/TX	TX	Text	Word	S CITRULLINATED(W)PEPTIDE/TX

¹Only in Files 173 & 973.

²Use the UDF (NA or DG) or KWIC to display.

³Only found in DT=ONGOING TRIAL records.

⁴Only in Files 373 and 873.

ADDITIONAL INDEXES [top]

SEARCH PREFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
AA=	AA	Adis Accession Number	Phrase	S AA= 801040717
AC=	AC	ATC WHO Codes¹	Phrase	S AC= L01BA01
AE=	AE	Adis Assessment⁵	Word & Phrase	S AE=(PHARMACOLOGICAL(W) INTERVEN?) S AE=THIS STUDY WAS PRESENTED?
AS=	AS	Therapeutic Area	Phrase	S AS=RHEUMATIC DISEASE
AU=	AU	Author	Phrase	S AU=VAN DONGEN H
None	AZ	DIALOG Accession Number
CC=	CC	EphMRA Codes¹	Phrase	S CC=L01B
CD=	CD	Adis Creation Date^1,6	Phrase	S CD=20060707
CI=	CI	Clinical Relevance	Phrase	S CI=A
CR=	CR	References^1,3	Word	S CR=(ELI(W)LILLY)
CS=	CS	Corporate Source⁷	Word	S CS=(LEIDEN(W)UNIVERSITY) S CS=LEIDEN UNIVERSITY MEDICAL?
None	DG	Dose Units, Drug Route, Maximum Dose, Minimun Dose^1,2
DT=	DT	Document Type⁸	Phrase	S DT=BEST EVIDENCE
ES=	ES	Adis Score	Phrase	S ES=72
JN=	JN	Journal Name	Phrase	S JN=ANNALS OF THE RHEUMATIC DISEAS?
LA=	LA	Language	Phrase	S LA=ENGLISH
LK=	LK	R&D Insight Link^1,12	Phrase	S LK=020557
MT=	MT	Meeting Name¹	Word	S MT=(ANNUAL(W)EUROPEAN(S)RHEUMA?)
NA=	DG	Drug Name^1,2	Phrase	S NA=METHOTREXATE
NG=	NG	Number of Patient Groups⁴	Phrase	S NG=7
NP=	NP	Number of Patients¹	Phrase	S NP=110
NS=	NS	Study Name^1,13	Word & Phrase	S NS=(PROBABLE(W)RA(F) METHOTREXATE) S NS=PROBABLE RA?
NT=	NT	Adis Comment	Word	S NT=(ANTIMETABOLITE(W)AGENT)
OT=	OT	Outcome⁵	Phrase	S OT="METHOTREXATE > PLACEBO"
PD=	PD	Publication Date	Phrase	S PD=20060701
PK=	PK	Patient Age Keywords	Phrase	S PK=ADULT
None	PM	Patient Minimum Age¹
PP=	PP	Planned Number of Patients¹	Numeric	S PP=1000
PS=	PS	Study Phase	Phrase	S PS=PHASE III
None	PX	Patient Maximum Age¹
PY=	PY	Publication Year	Phrase	S PY=2006
RH=	RH	Results Highlights^5,9	Word	S RH=(EROSIVE(W)DISEASE)
SI=	SI	Study Design	Phrase	S SI=RANDOMISED
SK=	SK	Study Endpoints⁹	Phrase	S SK=KAPLAN MEIER?
SM=	SM	Study Messages^5,9	Word	S SM=(METHOTREXATE(1W)BENEFICIAL)
SN=	SN	International Standard Serial Number¹	Phrase	S SN=0003-4967 S SN=00034967
SO=	SO	Source Information¹⁰	Word	S SO=(RHEUMATIC AND JUL(W)2006)
ST=	ST	Study Status¹	Phrase	S ST=IN PROGRESS
TL=	TL	Clinical Trials Number^1,11	Phrase	S TL=ID01-604
TY=	TY	Study Controls	Phrase	S TY=PLACEBO COMPARISON
UD=	None	Update	Phrase	S UD=9999
UP=	UP	Last Update Date^1,3	Phrase	S UP=20060323

⁵Also searchable as /EV.

⁶The date that the Adis record was created.

⁷The linking between authors and institutions is not present until October 2005.

⁸Files 173 & 973 include Best Evidence (beginning 1990), Supporting Evidence (beginning 2005), Ongoing Trials (beginning 2005), and Citation-only records (from 1990-2004). Beginning in 2005, Citation-only records are superseded by Supporting Evidence records. Files 373 & 873 include the former Summary and Citation records only.

⁹Available in records from 1996 forward.

¹⁰Search and Display include Journal Name, Volume, Issue, Pages, and Publication Date.

¹¹MAP RRTL in File 173/973 to find related records.

¹²MAP LK in File 107 to find related records.

¹³MAP RRNS in File 173/973 to find related records.

LIMIT [top]

SUFFIX	FIELD NAME	EXAMPLES
/BEST	Best Evidence Records	S S1/BEST
/CIT	Citation-only Records	S ANTIRHEUMATICS/CIT
/ONGOING	Ongoing Trials Records	S S3/ONGOING
/SUPPORT	Supporting Evidence Records	S UD=?/SUPPORT
/YYYY	Publication Year	S S4/2005:2006

SORT [top]

SORTABLE FIELDS	EXAMPLES
AU, CS, JN, PD, PY, TI	SORT S5/ALL/PY/D SORT S1/ALL/CS

RANK [top]

RANK FIELDS	EXAMPLES
All phrase- and numeric-indexed fields in the Additional Indexes can be ranked. Other RANK codes include: DE	RANK CS RANK AU S4

MAP [top]

MAP FIELDS	EXAMPLES
LK, RRNS, RRTL	MAP LK TEMP S2

USER-DEFINED FORMAT OPTIONS [top]


Display codes listed in the Search Options tables can be used to customize output.	TYPE S4/TI, EV, PY/1-5 PRINT S5/TI, AE, AS/ALL

PREDEFINED FORMAT OPTIONS [top]

NO.	DIALOGWEB FORMAT	RECORD CONTENT
1	--	DIALOG Accession Number
2	Short	Full Record except Text fields
3	Medium	Full Record except Text fields
4	--	Full Record Tagged
5	Long	Full Record
6	Free	Adis Accession Number, Adis Title, Original Title, Creation Date, Publication Date, Last Update Date (for Ongoing Trial records only), Document Type, Record Type, R&D Insight Link, WHO and EphMRA Codes
7	--	Full Record except indexing, i.e., /DE,(DI, /DU, /OD, /PR), AC=, CC=, TL=
8	Free	Adis Accession Number, Adis Title, Original Title, Creation Date, Publication Date, Document Type, Record Type, Last Update Date (for Ongoing Trial records only), Descriptors, WHO and EphMRA codes, R&D Insight Link, Language
9	Full	Full Record
K	--	KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats

DIRECT RECORD ACCESS [top]

FIELD NAME	EXAMPLES
If the accession number of a specific record is known, it can be used to display the record directly.	TYPE 016601/9 PRINT 016009/5

Rates [top]

Rates For File: Adis Clinical Trials Insight (1990-present)[173]
Cost per DialUnit:                $14.13
Cost per minute:                   $3.77
Rank Elements                      $0.07
ALERT (default)                   $10.00
ALERT (Monthly)                   $27.00
ALERT (Biweekly/twice a month) *  $16.00
ALERT (Weekly)                    $10.00
ALERT (Daily)                  *  $10.00
ALERT (Calendar weekly)        *  $10.00
ALERT (Intraday)               *  $10.00
* = custom scheduled Alerts only
ALERT Number of included prints        0

Format    Types   Prints
     1    $0.00    $0.00
     2    $2.00    $2.00
     3    $2.00    $2.00
     4   $25.00   $25.00
     5   $25.00   $25.00
     6    $0.00    $0.00
     7   $25.00   $25.00
     8    $0.00    $0.00
     9   $25.00   $25.00
    24   $25.00   $25.00
    25    $7.00    $7.00
    26   $12.00   $12.00
    27    $2.00    $2.00
    33   $25.00   $25.00
KWIC95    $0.40       NA
KWIC96    $8.00       NA

REDIST/COPY Multiplier Table:

      Range      Multiplier
        1-2       1.00
       3-25       1.50
     26-100       3.00
    101-200       4.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00
------------------------------

Supporting Evidence Records:
  Formats 4, 5, 7, 9 priced at $ 5.00
  UDFs priced at $ 5.00 are: NA, TX, SD, SJ, TR, TL, NS, NP, PK,
  SI, TY, PS, SK

Ongoing Trials Records:
  Formats 4, 5, 7, 9 priced at $10.00
  UDFs priced at $10.00 are: TX, SD, SJ, OC, TL, NS, ST, PK, SI,
  TY, PS, SK

Best Evidence Records:
  Formats 4, 5, 7, 9 priced at $20.00
  UDFs priced at $20.00 are: NA, EV, SM, RH, AE, NT, ES, OT, PU,
  CT, SD, SJ, TR, RE, AF, CI, TL, NS, NP, PM, UM, PX, UX, PK, SI,
  TY, PS, SK

Rates For File: Adis Clinical Trials Insight (1982-1989)[373]
Cost per DialUnit:                $13.70
Cost per minute:                   $3.52

Format    Types   Prints
     1    $0.00    $0.00
     2    $1.50    $1.50
     3    $1.50    $1.50
     4   $25.00   $25.00
     5   $25.00   $25.00
     6    $0.00    $0.00
     7   $25.00   $25.00
     8    $0.00    $0.00
     9   $25.00   $25.00
KWIC95    $0.45       NA
KWIC96    $9.00       NA

REDIST/COPY Multiplier Table:

      Range      Multiplier
        1-2       1.00
       3-25       1.50
     26-100       3.00
    101-200       4.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00

Rates For File: Adis Clinical Trials Insight (1982 - 1989) - subscribers[873]
Cost per DialUnit:                $13.97
Cost per minute:                   $3.57

Format    Types   Prints
     1    $0.00    $0.00
     2    $1.50    $1.50
     3    $1.50    $1.50
     4    $7.00    $7.00
     5    $7.00    $7.00
     6    $0.00    $0.00
     7    $7.00    $7.00
     8    $0.00    $0.00
     9    $7.00    $7.00
KWIC95    $0.50       NA
KWIC96    $1.50       NA

Rates For File: Adis Clinical Trials Insight (1990 - present) - subscribers[973]
Cost per DialUnit:                $13.70
Cost per minute:                   $3.52
Rank Elements                      $0.07
ALERT (default)                   $10.25
ALERT (Monthly)                   $27.00
ALERT (Biweekly/twice a month) *  $23.00
ALERT (Weekly)                    $10.25
ALERT (Daily)                  *  $10.25
ALERT (Calendar weekly)        *  $10.25
ALERT (Intraday)               *  $10.25
* = custom scheduled Alerts only
ALERT Number of included prints        0

Format    Types   Prints
     1    $0.00    $0.00
     2    $2.00    $2.00
     3    $2.00    $2.00
     4    $7.00    $7.00
     5    $7.00    $7.00
     6    $0.00    $0.00
     7    $7.00    $7.00
     8    $0.00    $0.00
     9    $7.00    $7.00
    24    $7.00    $7.00
    25    $3.50    $3.50
    26    $7.00    $7.00
    27    $2.00    $2.00
    33    $7.00    $7.00
KWIC95    $0.45       NA
KWIC96    $1.50       NA

[top]